Супрастинекс

Quick links

Choose a section

Quick links to important sections

Advertisements

Супрастинекс

Selected form

Advertisements
Advertisements

Overview of Супрастинекс

Quick Facts

Property Description
Active ingredient Levocetirizine Dihydrochloride
Form Tablets (oral) and solution for injection (parenteral)
Pharmacological class Second-generation H₁-receptor antagonist
General purpose Relief of symptoms associated with allergic reactions
Origin Synthetic R-enantiomer of Cetirizine

What Type of Medicine Is Супрастинекс and Its Core Composition?

Супрастинекс is the trade name for a medicinal product containing the highly potent active ingredient Levocetirizine Dihydrochloride, which is classified as a second-generation H₁-receptor antagonist. This classification is clinically recognized for its high specificity and reduced impact on the central nervous system compared to older antihistamines.

Levocetirizine is a synthetic compound and the purified R-enantiomer of Cetirizine. This structural feature is a key point of differentiation, as it isolates the most active part of the precursor drug, leading to a high binding affinity for the target receptors. This refined composition is designed to ensure effective and reliable suppression of the physiological cascade initiated by histamine.

In What Forms Is Супрастинекс Available and What Is Its General Purpose?

Супрастинекс is available as a systemic drug in two principal dosage forms: the solid oral form (tablets) for general use and a liquid parenteral form (solution for injection). The availability of the intravenous solution is a distinctive feature that facilitates rapid systemic administration when a swift therapeutic effect is necessary.

The drug's primary therapeutic function is to alleviate the discomfort caused by histamine-mediated conditions. By acting as a competitive H₁-blocker, Levocetirizine suppresses the early stages of the allergic response, thereby exerting an anti-exudative and anti-pruritic effect. The drug serves as an anti-allergic agent for reducing the main clinical manifestations of allergy. This supports the medicine's role in mitigating common allergic symptoms like itching and swelling.

Advertisements

What side effects are possible with Супрастинекс?

The safety profile of Levocetirizine Dihydrochloride, the active substance in Супрастинекс, is documented in official regulatory sources according to the likelihood of adverse effects based on clinical trial data and post-marketing surveillance. Adverse reactions are formally classified by frequency, ranging from Common to Not Known.

Frequency-Classified Adverse Reactions

Adverse effects most frequently observed in clinical trials were classified as Common (ge 1/100 to <1/10) and include somnolence (drowsiness), headache, fatigue, and dry mouth. Uncommon effects (ge 1/1,000 to <1/100) include asthenia (unusual weakness) and abdominal pain. These effects primarily involve the Nervous System and Gastrointestinal Disorders system-organ classes.

Serious Reactions and Post-Marketing Reports

Events reported during post-marketing surveillance are listed with a frequency of Not Known as incidence rates cannot be reliably estimated. These include hypersensitivity reactions, which may manifest as anaphylaxis or angioedema. Reports under Psychiatric Disorders include aggression, hallucination, and suicidal ideation. Other documented reports include palpitations, tachycardia, and seizures.

Safety Constraints and Special Populations

The medicine is contraindicated in patients with End-Stage Renal Disease (creatinine clearance <10 mL/min) or those on hemodialysis, as its elimination is highly dependent on renal function. Caution is noted for use in older adults due to the higher likelihood of reduced renal function. The label advises against the use of the drug with alcohol or other CNS depressants due to the risk of additive impairment of central nervous system performance. Furthermore, severe pruritus (intense itching) has been reported after cessation of long-term use.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The following information is derived exclusively from regulatory documents and describes the officially documented manifestations of overdose and the required emergency actions for Levocetirizine Dihydrochloride (Супрастинекс).


Documented Overdose Presentations

Population Documented Manifestation
Adults Primarily characterized by drowsiness, somnolence, and fatigue.
Children Exhibits a biphasic response: initial agitation or restlessness, followed by subsequent drowsiness.

Required Emergency Actions

Immediate medical attention must be sought for any suspected overdose. Regulator-mandated action requires contacting emergency services or poison control immediately if the individual experiences collapse, a seizure, trouble breathing, or cannot be awakened (loss of consciousness).

Treatment is strictly symptomatic and supportive. Official labeling specifies that no specific antidote is known for Levocetirizine. Healthcare professionals may consider measures such as gastric lavage for acute, recent oral ingestion. Furthermore, the substance is not effectively removed by haemodialysis.

Serious potential outcomes that may be exacerbated by overdose include convulsion, syncope, and the risk of urinary retention. Due to the potential for increased systemic exposure in children, strict adherence to prescribed doses is emphasized.

Advertisements

Therapeutic Uses of Супрастинекс

The medication is commonly used across domains involving heightened, disruptive symptoms and provides support that helps ease the overall symptom burden. Levocetirizine is applied across domains where additional symptomatic support is needed for managing allergic conditions.

The core therapeutic domains are relevant for managing the symptoms of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria (hives). It is commonly used to help with symptom clusters that may become intense or disruptive, including symptoms related to physical discomfort such as sneezing, runny nose, itchy eyes, and the widespread skin discomfort (pruritus) associated with chronic hives.

It is often used when symptoms intensify and supportive relief is needed, and may assist with managing symptom clusters like watery eyes, itchy throat, and generalized skin irritation, applying across a wide spectrum of ages, including adults, adolescents, and children.

“The symptomatic relief provided by this therapy generally supports the patient during difficult episodes by easing distress.”

Quick Fact

Property Description
Primary Focus Symptoms related to inflammatory or irritative states
Key Benefit Contributes to improved comfort during periods of heightened symptoms
Common Use Context Conditions involving episodic or fluctuating manifestations

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

The eligibility for using Супрастинекс (levocetirizine) is strictly defined by regulatory documents, particularly concerning allergic reactions and kidney function. Official labeling identifies specific populations who must not use the medicine (contraindications) and groups that require special caution.

Formal Exclusions (Contraindications)

  • Hypersensitivity: The medicine is contraindicated in patients with a known allergy to the active substance, levocetirizine, its parent compound cetirizine, other piperazine derivatives, or any inactive ingredients.
  • End-Stage Renal Disease (ESRD): Use is contraindicated in adults and adolescents (12 years and older) with end-stage renal disease (creatinine clearance less than 10 mL/ min) and in patients undergoing hemodialysis, as the medicine is primarily cleared by the kidneys.
  • Pediatric Renal Impairment: It is also contraindicated in children aged 6 months to 11 years with any degree of impaired kidney function.

Age and Condition Restrictions

  • Infants: Safety and efficacy have not been established in infants younger than 6 months of age, and use is therefore not recommended.
  • Urinary Retention Risk: The medicine should be used with caution in patients with predisposing factors for urinary retention, such as spinal cord lesions or prostatic hyperplasia. Discontinuation is required if urinary retention develops.
  • Pregnancy and Lactation: Use during pregnancy requires caution and should only be undertaken if clearly necessary. The medicine is expected to be excreted in breast milk, and its use is not recommended during lactation.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents detail specific pharmacodynamic (PD) and pharmacokinetic (PK) interactions for Suprastinex (levocetirizine).


Pharmacodynamic and CNS Interactions

Concurrent use with alcohol or other central nervous system ( CNS) depressants should be avoided. This combination carries a risk of additive impairment, leading to further reductions in alertness and central nervous system performance.


Pharmacokinetic Exposure Modification

Interacting Substance Effect on Levocetirizine Exposure PK Relevance
Ritonavir Increases AUC by approximately 42% Significant increase in systemic exposure
Theophylline Small decrease in clearance (16%) Minor PK change

These interactions reflect changes observed in clinical studies and require awareness regarding potential accumulation.


Food and Administration Effect

While the extent of absorption ( AUC) is not reduced by food, the rate of absorption, including the time to reach maximum concentration ( T max), is decreased. Levocetirizine may be taken with or without food.


Population-Specific Constraints

Due to the drug's primary route of elimination via the kidneys, the dosage interval must be carefully individualized based on renal function (creatinine clearance). Use is contraindicated in individuals with severe renal impairment ( CrCl < 10 mL/min) or those undergoing hemodialysis.

Advertisements

Mechanism of Action

Modulating Histamine Receptor Activity

The compound is a selective inverse agonist of the peripheral Histamine H1-receptor. This primary mechanism involves binding to the H1-receptor, which engages mechanisms that shift the receptor's equilibrium toward an inactive state. This action attenuates the initial molecular steps of histamine-driven signaling. This core pathway effect modulates mediator-driven cellular activity, resulting in a reduction of signal propagation.


Modulating Inflammatory Mediator Cascades

This domain describes the compound’s influence on various downstream processes that occur independently of H1-receptor antagonism. It influences systems where specific inflammatory transmitters or mediators are dominant by modulating signaling processes. Specifically, the compound can influence the release and activity of certain chemokines and leukotrienes, modifying early molecular steps that shape systemic physiological outcomes through altered feedback regulation within targeted pathways.


Influencing Inflammatory Cell Function

This cluster addresses the compound's role in mechanisms that regulate overactive cellular processes. By modulating mast cell degranulation and reducing the recruitment and activation of eosinophils, the compound influences key pathways associated with cellular inflammatory signaling. This action helps to reduce the cellular-level release of pre-formed and newly synthesized pro-inflammatory mediators, consequently altering the signaling sequences that lead to downstream physiological effects.

Advertisements

Dosage and Administration Information

How to Use Супрастинекс (Levocetirizine)

The usage of Levocetirizine Dihydrochloride is strictly governed by official administration guidelines, defining the route, dosing schedule, and context of intake. The medicine is designated solely for oral administration, available as film-coated 5 mg tablets and an oral solution. The primary dosing pattern across approved populations is once daily, with the standard regimen for adults and adolescents (12 years and older) being 5 mg taken in a single dose.


Administration Protocol

The full daily dose is generally recommended to be taken in the evening to align with its intended profile. Ingestion can occur with or without food, providing flexibility in the daily schedule. Tablets should be swallowed whole with liquid; however, the scored 5 mg tablet may be broken to administer the 2.5 mg dose if required by the prescribed regimen.

Dosing Patterns and Constraints

Usage Entity Map Official Administration Rules
Frequency Once daily (q.d.)
Maximum Adult Dose Strictly 5 mg per day
Renal Function Rule Dose frequency must be reduced based on the severity of renal impairment.
Use Duration Ranges from intermittent (as needed for episodic symptoms) to continuous (for chronic conditions, supported by clinical experience up to 6 months).

For patients with mild to severe renal impairment, the prescribed dose or frequency is structurally adjusted to maintain appropriate systemic exposure. Use is precluded in patients with end-stage renal disease (CrCl < 10 mL/min). This structured protocol ensures the medicine is used in accordance with established guidelines and specific patient characteristics.

Advertisements

Recent Clinical Evidence

Research Evidence and Clinical Studies Summary

This section outlines key clinical and non-clinical research that has examined the combination pain management solution.

Studies on Pharmacodynamics and Clinical Evaluation

Research has explored whether the combination of two established mechanisms could be the subject of a pain management study, and research evaluated specific clinical endpoints.

  • Study Design: Clinical trials evaluated whether the combination formulation was associated with a difference in the timing of pain reduction compared to placebo in patients with moderate to severe acute pain. They also examined whether there was a reduction in discomfort over a 12-hour period.
  • Patient Population: Studies included most adults across a range of ages. The studies primarily focused on individuals without pre-existing renal conditions. The primary focus was on short-term, acute pain relief.

Studies of Acute Pain

Phase 3 studies documented a mean change of 45% in pain scores (Visual Analog Scale) at 4 hours post-administration, in a study that included standard over-the-counter treatments as a comparator group.

Data Point Measure Comparison Group
Mean Pain Change 45% at 4 hours Standard OTC Treatment
Primary Endpoint SPID (Summed Pain Intensity Difference) Placebo and Single-Agent Control
  • Dosing Protocol: The protocol for the study utilized a regimen of one tablet every 12 hours for durations up to 5 days.
  • Primary Endpoint: The main goal of the pivotal trials was to compare the summed pain intensity difference (SPID) over a 48-hour period against both placebo and a single-agent control group.

Study of Duration of Action and Half-Life Data

Data from pharmacokinetic studies explored the duration of action, which was aligned with the twice-daily dosing protocol examined in the trials. Investigators also examined the compound in research models related to chronic pain.

  • Mechanism of Action: Research also examined the compound's actions on inflammatory markers. Researchers evaluated whether this was associated with an altered therapeutic effect.
  • Co-administration Notes: The trial protocol included a requirement for participants to abstain from alcohol consumption.

Key Studies & References

  1. Guideline: Oral Analgesics for Acute Dental Pain (Supports Acute Pain Management Context)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Супрастинекс (FAQ)


Q: How quickly should I expect to feel the effects of Супрастинекс?

Official information indicates that the active ingredient in Супрастинекс is rapidly absorbed after use. Studies have shown that the concentration in the body reaches its peak (T max) in less than one hour for both the tablet and the oral solution. This rapid absorption is consistent with the drug's intended action profile.

Q: Does Супрастинекс cause drowsiness or make you sleepy?

Yes, drowsiness, known as somnolence, is listed in regulatory documents as a Common side effect, along with fatigue. Official information advises caution regarding activities requiring complete mental alertness.

Q: Is it true that Супрастинекс is less sedating than some other antihistamines?

The medicine is classified as a second-generation H1-receptor antagonist. This class is typically associated with a lower potential for central nervous system effects, such as drowsiness, compared to older, first-generation antihistamines.

Q: How long does the effect of one use of Супрастинекс usually last?

Pharmacokinetic data summarized in official references state that the duration of action for a single dose is approximately 24 hours. This duration of effect supports the medicine's primary use on a once-daily dosing regimen.

Q: Does Супрастинекс affect my ability to drive or operate machinery?

Official warnings state that caution should be exercised before engaging in hazardous occupations that require complete mental alertness and motor coordination. This caution relates to the potential for side effects such as drowsiness or fatigue, which may impair concentration.

Q: What kind of safety information is available for long-term use of Супрастинекс?

Clinical safety data from studies has examined the use of the medicine for continuous periods of up to six months. This data was collected during research involving adults and adolescents being treated for chronic allergic conditions.

Q: Does taking Супрастинекс daily make it less effective over time?

The medicine is used for both short-term and continuous management of chronic conditions. Clinical evidence from studies suggests sustained effectiveness when used continuously.

Q: What is the typical time frame before deciding if Супрастинекс is working?

In clinical studies for allergic rhinitis, the active substance showed an effect compared to placebo as early as the first day of administration. Symptom relief was documented to continue throughout the treatment periods examined in the studies.

Q: Is Супрастинекс the same as other allergy medicines I've heard of?

The active ingredient in Супрастинекс is levocetirizine dihydrochloride. It is classified as a second-generation H1-antihistamine. While it shares the general purpose of other allergy medicines, its specific chemical properties and central nervous system profile may differ from other drugs in the same class or older antihistamine types.

Q: Is it safe to take Супрастинекс every day for a long period?

Clinical studies have examined the long-term safety profile for continuous use of up to six months in relevant adult populations for chronic conditions. Use is based on the prescribed regimen and official guidance.

Q: Can Супрастинекс be used for skin rashes and hives?

Yes, official regulatory documents state that the medicine is indicated for the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria (hives). The medicine is also indicated for the relief of general allergy symptoms.

Q: Does Супрастинекс interact with common pain relievers like ibuprofen?

Official drug interaction studies only specify known interactions with substances such as ritonavir, theophylline, and central nervous system depressants. Common pain relievers such as ibuprofen are not listed as interacting substances in the official studies that detail known interactions.

Q: Is Супрастинекс appropriate for treating all types of allergies?

The medicine is specifically indicated for the relief of symptoms associated with seasonal allergic rhinitis, perennial (year-round) allergic rhinitis, and chronic idiopathic urticaria (hives). The medicine is used for the symptoms associated with these established indications.

Q: Is there any research on how well Супрастинекс works for chronic hives?

Yes, the medicine is formally indicated for the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria (hives). Clinical studies have examined its effectiveness for reducing symptoms like the severity of itching and the size of wheals associated with this condition.

Q: Does Супрастинекс affect the results of allergy skin tests?

Authoritative medical information consistently advises that antihistamines like levocetirizine can interfere with the results of allergy skin prick testing. Use of the active substance should typically be stopped for a number of days before this type of test is performed.

Q: Are there any specific foods I should avoid when taking Супрастинекс?

No specific foods are required to be avoided. Regulatory studies show that while food may slow down the rate of absorption, it does not affect the total amount of the drug absorbed into the body. The medicine may be taken with or without food.

Q: Is Супрастинекс used only for seasonal allergies?

No. Official indications show that the medicine is used for both seasonal allergic rhinitis (e.g., hay fever) and perennial (year-round) allergic rhinitis. It is also indicated for the treatment of chronic idiopathic urticaria (hives).

Q: Is there a maximum age limit for using Супрастинекс?

There is no formal maximum age limit contraindication. However, official labeling advises that caution should be exercised in older adults (geriatric patients) due to the higher likelihood of reduced kidney function, which may require adjustment.

Q: Why is Супрастинекс sometimes prescribed instead of older allergy drugs?

The active substance is a purified part of a second-generation antihistamine. This generation is often used because it is typically associated with a reduced potential for causing central nervous system effects, such as drowsiness, compared to older antihistamines.

Q: Can Супрастинекс be taken with cold and flu medicine?

The medicine should be used with caution when combined with other drugs. Official information states that the concurrent use of the drug with alcohol or other CNS depressants carries a risk of additive impairment of central nervous system performance.

Q: Is Супрастинекс available without a prescription?

The availability of the drug containing levocetirizine varies by regulatory jurisdiction. In some areas, the active ingredient may be available in both prescription and over-the-counter (OTC) formulations.

Q: Are there different strengths of Супрастинекс available?

Official documents state that the active ingredient is available in different dosage forms. These typically include a standard 5 mg oral tablet and an oral solution (e.g., 2.5 mg/5 mL).

Q: Can Супрастинекс help with pet allergies?

The medicine is indicated for the relief of symptoms associated with perennial (year-round) allergic rhinitis. Symptoms caused by common indoor allergens like pet dander are classified under perennial rhinitis.

Q: Can people with liver problems use Супрастинекс?

Official drug information states that a dose adjustment is generally not required for patients who have only hepatic (liver) impairment. However, dose adjustment may be necessary if a patient has co-existing liver and kidney impairment.

Q: Does Супрастинекс interact with any antacids?

Official drug interaction studies do not list antacids as interacting substances. Known interactions are specified for a limited number of drugs, including ritonavir, theophylline, and central nervous system depressants.

Q: Can Супрастинекс be used to treat hay fever symptoms?

Yes. The medicine is formally indicated for the relief of symptoms associated with seasonal allergic rhinitis, which is the condition commonly referred to as hay fever.

Q: Is it okay to stop using Супрастинекс suddenly?

Post-marketing reports have documented instances of severe pruritus (intense generalized itching) in some patients after they stopped using the active substance following long-term use. This is reported as an adverse reaction upon cessation.

Q: Can Супрастинекс cause changes in appetite or weight?

Post-marketing reports and clinical data have documented instances of weight gain as an adverse reaction to the active substance. This effect, though reported at a low incidence, is included in official safety information.

Q: Can Супрастинекс be used for insect bite reactions?

The medicine is an antihistamine used to reduce common allergy symptoms such as itching and hives. The drug's indication for general allergy relief includes the reduction of symptoms such as itching, which are common manifestations of insect bite reactions.

Q: Does Супрастинекс have any cardiovascular side effects?

Post-marketing reports have documented cardiovascular-related effects, including palpitations (rapid heart action) and tachycardia (fast heart rate). Additionally, hypotension (low blood pressure) has been reported, generally at a frequency of 'Not Known' or 'Rare'.

Q: Is Супрастинекс a cure for allergies or just a treatment for symptoms?

Official regulatory documents define the medicine's role as providing relief of symptoms associated with allergic rhinitis and the treatment of uncomplicated skin manifestations of chronic idiopathic urticaria. It is a symptomatic treatment, not a cure for the underlying allergic condition.

Q: Does Супрастинекс affect blood pressure?

Post-marketing reports document cases of hypotension (low blood pressure) as an adverse effect of the active substance. These reports are generally categorized as having a 'Not Known' or 'Rare' frequency.

Q: What does the research say about the effectiveness of Супрастинекс?

Clinical studies have documented the effectiveness of the active ingredient in providing relief of symptoms of allergic rhinitis, such as sneezing and itchy nose. Research also showed its effectiveness in reducing the severity of itching and the size of wheals in patients with chronic idiopathic urticaria (hives).

Advertisements

How should Супрастинекс be stored and disposed of?

How to Store and Dispose of Супрастинекс?

Супрастинекс (levocetirizine dihydrochloride) must be stored and disposed of according to official regulatory guidelines to maintain its stability and ensure safety.

Storage Requirements

Storage Rule Official Requirement
Temperature Store at controlled room temperature: 68 F to 77 F (20 C to 25 C).
Protection Keep from freezing, and store away from excess heat and moisture.
Container Keep in the original container, tightly closed.
Safety Store out of the sight and reach of children.

Disposal

Unused or expired product should be discarded following recommended procedures. Regulators encourage the use of drug take-back programs. If a program is unavailable, the medicine must not be flushed down a toilet or sink. Instead, mix the product with an unappealing substance, place it in a sealed container, and discard it in the household trash. Personal information must be removed from the packaging before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Супрастинекс found in:

A-Z Index: